Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Kidney Cancer, Bladder Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 2 - 100 |
| Updated: | 4/6/2019 |
| Start Date: | March 12, 1998 |
| Contact: | Deborah A Nielsen, R.N. |
| Email: | deborah.nielsen@nih.gov |
| Phone: | (240) 760-6247 |
Selected patients suspected of having or with prior biopsy proof of malignant disease will be
seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the
initial visit and at periodic intervals during the course of the disease. These samples will
be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and
normal tissue will be collected at the time of surgery and stored in the tissue bank,
Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the
Urologic Oncology Branch, NCI....
seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the
initial visit and at periodic intervals during the course of the disease. These samples will
be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and
normal tissue will be collected at the time of surgery and stored in the tissue bank,
Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the
Urologic Oncology Branch, NCI....
Background
- Kidney, prostate, bladder, testis and penile cancer account for 22% of cancers diagnosed in
the United States and are responsible for 10% of cancer deaths each year in the U.S.
Understanding the genes and gene pathways that cause genitourinary malignancies will provide
the foundation for the development of targeted therapeutic agents for patients affected with
these cancers. Since 1982 investigators in the Urologic Oncology Branch have been studying
the genetic basis of urologic cancers. The identification of the genes for cancer of the
kidney has led to the approval by the FDA of a number of new agents for patients with
advanced disease. It is our goal to study the cancer gene pathways of genitourinary
malignancies in order to further understand the cancer gene pathways that cause these
diseases.
Objectives
- Collection of benign and malignant tissue from patients with known or suspected cancer.
- Collection of benign and malignant tissue from patients with rare inherited conditions
associated with an increased risk for kidney cancer.
- Determine the molecular genetic differences between normal and tumorigenic tissues.
- Investigate the categories of genes/ biochemical pathways such as those that influence
the cell cycle, angiogenesis, metabolic changes, and metastatic potential.
- Examine protein expression and bioimmunoassays investigating potential genetic markers.
- Investigate cellular/biochemical response to existing and novel therapeutic agents.
- Investigate quality of life in men who have prostate cancer.
- Investigate molecular genetic basis of urologic malignancies
Eligibility
- Patients with biopsy-proven malignant disease.
- Patients suspected of having malignant disease.
- Patients with known or suspected urologic malignant disorders who have clinically
indicated urologic or non-urologic surgical lesion.
- Family members of patients suspected of having an inherited genitourinary malignancy
- Family members of patients with a DNA variant
Design
- Patients will be screened for eligibility in the Urologic Oncology Branch Clinic.
- Blood and urine samples may be obtained.
- Normal and malignant tissue may be collected from patients undergoing clinically
indicated surgical procedures.
- Basic scientific research will be performed on collected specimens.
- Patients will have the option to be contacted if a result is detected that would affect
their health and they will be given the opportunity to be evaluated and re-tested on an
IRB approved protocol if available.
- Germline and somatic whole genome exome sequencing may be performed
- Kidney, prostate, bladder, testis and penile cancer account for 22% of cancers diagnosed in
the United States and are responsible for 10% of cancer deaths each year in the U.S.
Understanding the genes and gene pathways that cause genitourinary malignancies will provide
the foundation for the development of targeted therapeutic agents for patients affected with
these cancers. Since 1982 investigators in the Urologic Oncology Branch have been studying
the genetic basis of urologic cancers. The identification of the genes for cancer of the
kidney has led to the approval by the FDA of a number of new agents for patients with
advanced disease. It is our goal to study the cancer gene pathways of genitourinary
malignancies in order to further understand the cancer gene pathways that cause these
diseases.
Objectives
- Collection of benign and malignant tissue from patients with known or suspected cancer.
- Collection of benign and malignant tissue from patients with rare inherited conditions
associated with an increased risk for kidney cancer.
- Determine the molecular genetic differences between normal and tumorigenic tissues.
- Investigate the categories of genes/ biochemical pathways such as those that influence
the cell cycle, angiogenesis, metabolic changes, and metastatic potential.
- Examine protein expression and bioimmunoassays investigating potential genetic markers.
- Investigate cellular/biochemical response to existing and novel therapeutic agents.
- Investigate quality of life in men who have prostate cancer.
- Investigate molecular genetic basis of urologic malignancies
Eligibility
- Patients with biopsy-proven malignant disease.
- Patients suspected of having malignant disease.
- Patients with known or suspected urologic malignant disorders who have clinically
indicated urologic or non-urologic surgical lesion.
- Family members of patients suspected of having an inherited genitourinary malignancy
- Family members of patients with a DNA variant
Design
- Patients will be screened for eligibility in the Urologic Oncology Branch Clinic.
- Blood and urine samples may be obtained.
- Normal and malignant tissue may be collected from patients undergoing clinically
indicated surgical procedures.
- Basic scientific research will be performed on collected specimens.
- Patients will have the option to be contacted if a result is detected that would affect
their health and they will be given the opportunity to be evaluated and re-tested on an
IRB approved protocol if available.
- Germline and somatic whole genome exome sequencing may be performed
- INCLUSION CRITERIA:
- Adult and minor patients with biopsy-proven malignant disease
- Adult and minor patients suspected of having a malignant lesion
- Patients who have or who are suspected of having an inherited urologic malignant
disorder
- Family members of patients suspected of having an inherited genitourinary malignancy
EXCLUSION CRITERIA:
- Subjects whose co-morbidities preclude surgical intervention.
- Subjects are unable or unwilling to provide consent.
- Pregnant women are excluded from enrollment onto this study because there is no
direct benefit for participating in the study
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Phone: (888) NCI-1937
Click here to add this to my saved trials
